BGLC logo

BioNexus Gene Lab (BGLC) Cash From Investing

Annual CFI

-$382.60 K
+$67.90 K+15.07%

31 December 2023

BGLC Cash From Investing Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly CFI

-$183.10 K
-$266.20 K-320.34%

30 September 2024

BGLC Quarterly CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM CFI

-$89.70 K
+$177.60 K+66.44%

30 September 2024

BGLC TTM CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

BGLC Cash From Investing Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+15.1%+49.2%+78.6%
3 y3 years-129.0%-212.5%+89.2%
5 y5 years-640.0%-5331.4%-1473.7%

BGLC Cash From Investing High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-129.0%+22.0%-320.3%+49.2%-125.9%+89.2%
5 y5 years-129.0%+22.0%-110.7%+56.0%-105.2%+89.2%
alltimeall time-129.0%+22.0%-110.7%+56.0%-105.2%+89.2%

BioNexus Gene Lab Cash From Investing History

DateAnnualQuarterlyTTM
Sept 2024
-
-$183.10 K(-320.3%)
-$89.70 K(-66.4%)
June 2024
-
$83.10 K(+244.8%)
-$267.30 K(-24.4%)
Mar 2024
-
$24.10 K(-274.6%)
-$353.50 K(-7.6%)
Dec 2023
-$382.60 K(-15.1%)
-$13.80 K(-96.2%)
-$382.70 K(-8.6%)
Sept 2023
-
-$360.70 K(>+9900.0%)
-$418.80 K(+954.9%)
June 2023
-
-$3100.00(-39.2%)
-$39.70 K(-84.6%)
Mar 2023
-
-$5100.00(-89.8%)
-$258.40 K(-42.6%)
Dec 2022
-$450.50 K(-8.2%)
-$49.90 K(-371.2%)
-$450.40 K(-5.5%)
Sept 2022
-
$18.40 K(-108.3%)
-$476.80 K(-13.9%)
June 2022
-
-$221.80 K(+12.5%)
-$553.80 K(+41.3%)
Mar 2022
-
-$197.10 K(+158.3%)
-$391.90 K(-20.1%)
Dec 2021
-$490.60 K
-
-
DateAnnualQuarterlyTTM
Dec 2021
-
-$76.30 K(+30.2%)
-$490.60 K(-40.9%)
Sept 2021
-
-$58.60 K(-2.2%)
-$830.80 K(+8.2%)
June 2021
-
-$59.90 K(-79.7%)
-$767.80 K(+11.6%)
Mar 2021
-
-$295.80 K(-29.0%)
-$688.00 K(-152.1%)
Dec 2020
$1.32 M(<-9900.0%)
-$416.50 K(-9565.9%)
$1.32 M(-23.7%)
Sept 2020
-
$4400.00(-77.9%)
$1.73 M(+0.1%)
June 2020
-
$19.90 K(-98.8%)
$1.73 M(+0.8%)
Mar 2020
-
$1.71 M(<-9900.0%)
$1.71 M(<-9900.0%)
Dec 2019
-$12.80 K(-75.2%)
-$7100.00(-302.9%)
-$12.80 K(+124.6%)
Sept 2019
-
$3500.00(-35.2%)
-$5700.00(-38.0%)
June 2019
-
$5400.00(-137.0%)
-$9200.00(-37.0%)
Mar 2019
-
-$14.60 K
-$14.60 K
Dec 2018
-$51.70 K
-
-

FAQ

  • What is BioNexus Gene Lab annual cash flow from investing activities?
  • What is the all time high annual CFI for BioNexus Gene Lab?
  • What is BioNexus Gene Lab annual CFI year-on-year change?
  • What is BioNexus Gene Lab quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for BioNexus Gene Lab?
  • What is BioNexus Gene Lab quarterly CFI year-on-year change?
  • What is BioNexus Gene Lab TTM cash flow from investing activities?
  • What is the all time high TTM CFI for BioNexus Gene Lab?
  • What is BioNexus Gene Lab TTM CFI year-on-year change?

What is BioNexus Gene Lab annual cash flow from investing activities?

The current annual CFI of BGLC is -$382.60 K

What is the all time high annual CFI for BioNexus Gene Lab?

BioNexus Gene Lab all-time high annual cash flow from investing activities is $1.32 M

What is BioNexus Gene Lab annual CFI year-on-year change?

Over the past year, BGLC annual cash flow from investing activities has changed by +$67.90 K (+15.07%)

What is BioNexus Gene Lab quarterly cash flow from investing activities?

The current quarterly CFI of BGLC is -$183.10 K

What is the all time high quarterly CFI for BioNexus Gene Lab?

BioNexus Gene Lab all-time high quarterly cash flow from investing activities is $1.71 M

What is BioNexus Gene Lab quarterly CFI year-on-year change?

Over the past year, BGLC quarterly cash flow from investing activities has changed by +$177.60 K (+49.24%)

What is BioNexus Gene Lab TTM cash flow from investing activities?

The current TTM CFI of BGLC is -$89.70 K

What is the all time high TTM CFI for BioNexus Gene Lab?

BioNexus Gene Lab all-time high TTM cash flow from investing activities is $1.73 M

What is BioNexus Gene Lab TTM CFI year-on-year change?

Over the past year, BGLC TTM cash flow from investing activities has changed by +$329.10 K (+78.58%)